MUCOPOLYSACCHARIDOSES COMPRISE A GROUP OF LYSOSOMAL STORAGE DISORDERS CAUSED BY THE DEFICIENCY OF SPECIFIC LYSOSOMAL ENZYMES REQUIRED FOR THE CATABOLISM OF GLYCOSAMINOGLYCANS (GAG). MUCOPOLYSACCHARIDOSIS IVA (MPS IVA, MORQUIO A SYNDROME) IS CHARACTERIZED BY THE ABSENCE OR MARKED REDUCTION IN N-ACETYLGALACTOSAMINE-6-SULFATASE ACTIVITY. THE SULFATASE ACTIVITY DEFICIENCY RESULTS IN THE ACCUMULATION OF THE GAG SUBSTRATES, KS AND C6S, IN THE LYSOSOMAL COMPARTMENT OF CELLS THROUGHOUT THE BODY. THE ACCUMULATION LEADS TO WIDESPREAD CELLULAR, TISSUE, AND ORGAN DYSFUNCTION. VIMIZIM IS INTENDED TO PROVIDE THE EXOGENOUS ENZYME N-ACETYLGALACTOSAMINE-6-SULFATASE THAT WILL BE TAKEN UP INTO THE LYSOSOMES AND INCREASE THE CATABOLISM OF THE GAGS KS AND C6S. ELOSULFASE ALFA UPTAKE BY CELLS INTO LYSOSOMES IS MEDIATED BY THE BINDING OF MANNOSE-6-PHOSPHATE-TERMINATED OLIGOSACCHARIDE CHAINS OF ELOSULFASE ALFA TO MANNOSE-6-PHOSPHATE RECEPTORS.
TREATMENT OF MPS IVA CHONDROCYTES WITH ELOSULFASE ALFA INDUCED CLEARANCE OF KS LYSOSOMAL STORAGE FROM THE CHONDROCYTES.